Candida species cause vulvovaginitis and resistance to antifungals used for treatment

Keywords: Candida spp., Microbial sensitivity tests, Polymerase chain reaction, Vulvovaginal candidiasis

Abstract

In this study were identified Candida species from vaginal secretion isolates, evaluated their in vitro antifungal susceptibilities, and correlated these features with antifungal agents prescribed for patients assisted in a primary care service. Species identification by Polymerase Chain Reaction showed that 36.5% of isolates were characterized as non-C. albicans species. In antifungal susceptibility tests most isolates were susceptible to ketoconazole, fluconazole, and itraconazole, although between 40% and 50% of isolates show resistance or dose-dependent susceptibility to miconazole and nystatin, respectively. Analysis of drugs prescribed to patients revealed that 34.2% of the isolates were considered resistant to agents used in treatment. Several Candida species can cause vulvovaginitis and exhibit different susceptibility profiles to antifungal drugs used in treatment. The identification of Candida species is relevant and useful to the epidemiological management of infections. The antifungal susceptibility test may also be useful for choosing most effective drug treatment for each patient.

Author Biographies

Diogo Luan de Oliveira, Universidade Comunitária da Região de Chapecó - UNOCHAPECÓ
Pharmacist. Post graduated in Clinical Analysis. Health Sciences. Universidade Comunitária da Região de Chapecó (UNOCHAPECÓ), Chapecó SC Brazil.
Juliana Cristina Schmidt, Universidade Comunitária da Região de Chapecó - UNOCHAPECÓ
Doctor´s degree in Cell and Molecular Biology (UFPR). Professor in Health Sciences and in Postgraduate Courses featuring Laboratory Clinical Diagnosis and Pharmacology at the Universidade Comunitária da Região de Chapecó (UNOCHAPECÓ), Chapecó SC Brazil.

References

1. Sobel JD. Recurrent vulvovaginal candidiasis. Am J Obstet Gynecol. 2016;214(1):15-21.

2. Foxman B, Muraglia R, Dietz JP, Sobel JD, Wagner J. Prevalence of recurrent vulvovaginal candidiasis in 5 European countries and the United States: results from an internet panel survey. J Low Genit Tract Dis. 2013;17(3):340-5.

3. Gunther LS, Martins HP, Gimenes F, Abreu AL, Consolaro ME, Svidzinski TI. Prevalence of Candida albicans and non-albicans isolates from vaginal secretions: comparative evaluation of colonization, vaginal candidiasis and recurrent vaginal candidiasis in diabetic and non-diabetic women. Sao Paulo Med J. 2014;132(2):116-20.

4. Aguin TJ, Sobel JD. Vulvovaginal candidiasis in pregnancy. Curr Infect Dis Rep. 2015;17(6):462.

5. Hofs S, Mogavero S, Hube B. Interaction of Candida albicans with host cells: virulence factors, host defense, escape strategies, and the microbiota. J Microbiol. 2016;54(3):149-69.

6. Goncalves B, Ferreira C, Alves CT, Henriques M, Azeredo J, Silva S. Vulvovaginal candidiasis: Epidemiology, microbiology and risk factors. Crit Rev Microbiol. 2016;42(6):905-27.

7. Liu XP, Fan SR, Peng YT, Zhang HP. Species distribution and susceptibility of Candida isolates from patient with vulvovaginal candidiasis in Southern China from 2003 to 2012. J Mycol Med. 2014;24(2):106-11.

8. Bitew A, Abebaw Y. Vulvovaginal candidiasis: species distribution of Candida and their antifungal susceptibility pattern. BMC women's health. 2018;18(1):94.

9. Makanjuola O, Bongomin F, Fayemiwo SA: An Update on the Roles of Non-albicans Candida Species in Vulvovaginitis, J Fungi. 2018; 4(4):121.

10. Whaley SG, Berkow EL, Rybak JM, Nishimoto AT, Barker KS, Rogers PD. Azole Antifungal Resistance in Candida albicans and Emerging Non-albicans Candida Species. Front Microbiol. 2016;7:2173.

11. Dias LB, Melhem MdSC, Szeszs MW, Meirelles Filho J, Hahn RC. Vulvovaginal candidiasis in Mato Grosso, Brazil: pregnancy status, causative especies and drugstests. Braz J of Microbiol. 2011;42(4):1300-7.

12. Li Y, Leaw S, Chen J-H, Chang H, Chang T-C. Rapid identification of yeasts commonly found in positive blood cultures by amplification of the internal transcribed spacer regions 1 and 2. Eur J Clin Microbiol Infect Dis. 2003;22(11):693-6.

13. Bougnoux M-E, Dupont C, Mateo J, Saulnier P, Faivre V, Payen D, et al. Serumis more suitable than whole blood for diagnosis of systemic candidiasis by nested PCR. J Clin Microbiol. 1999;37(4):925-30.

14. Luo G, Mitchell TG. Rapid identification of pathogenic fungi directly from cultures by using multiplex PCR. J Clin Microbiol. 2002;40(8):2860-5.

15. CLSI. Method for antifungal disk diffusion susceptibility testing of yeasts: approved standard, M44-A. Clinical and Laboratory Standards Institute, Wayne, PA; 2004.

16. Andrioli JL, Oliveira GSA, Barreto CS, Sousa ZL, Oliveira MCHd, Cazorla IM, et al. Frequência de leveduras em fluido vaginal de mulheres com e sem suspeita clínica de candidíase vulvovaginal. Rev Bras Ginecol Obstet. 2009;31:300-4.

17. Mtibaa L, Fakhfakh N, Kallel A, Belhadj S, Belhaj Salah N, Bada N, et al. Vulvovaginal candidiasis: Etiology, symptomatology and risk factors. J Mycol Med. 2017;27(2):153-8.

18. Chatzivasileiou P, Vyzantiadis TA. Vaginal yeast colonisation: from a potential harmless condition to clinical implications and management approaches-A literature review. Mycoses. 2019;62(8):638-50.

19. Hii IM, Liu CE, Lee YL, Liu WL, Wu PF, Hsieh MH, et al. Resistance rates of non-albicans Candida infections in Taiwan after there vision of 2012 Clinical and Laboratory Standards Institute breakpoints. Infect Drug Resist. 2019;12:235-40.

20. Dota D, Fátima K, Shinobu CS, Patussi EV, Lopes Consolaro ME, Estivalet Svidzinski TI. Susceptibilidad de levaduras vaginales a los antifúngicos más utilizados en Maringá, Paraná, Brasil. Acta Bioquím Clín Latinoam. 2008;42(4):561-6.

21. Gamarra S, Morano S, Dudiuk C, Mancilla E, Nardin ME, de Los Angeles Mendez E, et al. Epidemiology and antifungal susceptibilities of yeasts causing vulvovaginitis in a teaching hospital. Mycopathologia. 2014;178(3-4):251-8.

22. Zhang JY, Liu JH, Liu FD, Xia YH, Wang J, Liu X, et al. Vulvovaginal candidiasis: species distribution, fluconazole resistance and drug efflux pump gene overexpression. Mycoses. 2014;57(10):584-91.

23. Maraki S, Mavromanolaki VE, Stafylaki D, Nioti E, Hamilos G, Kasimati A. Epidemiology and antifungal susceptibility patterns of Candida isolates from Greek women with vulvovaginal candidiasis. Mycoses. 2019;62(8):692-7.

24. Ferrazza M, Maluf MLF, Consolaro MEL, Shinobu CS, Svidzinski TIE, Batista MR. Caracterização de leveduras isoladas da vagina e sua associação com candidíase vulvovaginal em duas cidades do sul do Brasil. Rev Bras Ginecol Obstet. 2005;27(2):58-63.

Published
2021-12-20
Section
Artigos Originais